All Cases

Oncology

Developed regional market access strategies in several emerging markets to ensure strong market access for our multinational pharmaceutical company client

Estimated NSCLC burden in Mexico based on RWE to inform clinical management and drive market share of more effective therapies

Companion diagnostic strategy for launch of novel biomarker-driven oncology drug

Prioritization of tumor types for a tumor agnostic oncology asset to focus promotional efforts

Indication prioritization for an early-stage oncology asset

Fast-to-market opportunity assessment of an orphan disease with a pipeline oncology drug

Lifecycle planning for a pipeline solid cancer therapy asset

Biomarker and combination assessment to define a data generation for a Prostate Cancer asset

Defined business unit and opportunity prioritization to expand the Brain Cancer portfolio of a large manufacturer

Evaluated 10 potential indications for a clinical-stage Biotech seeking to prioritize the clinical path to market and potential return of two assets